Targeting macrophages in cancer immunotherapy
Z Duan, Y Luo - Signal transduction and targeted therapy, 2021 - nature.com
Immunotherapy is regarded as the most promising treatment for cancers. Various cancer
immunotherapies, including adoptive cellular immunotherapy, tumor vaccines, antibodies …
immunotherapies, including adoptive cellular immunotherapy, tumor vaccines, antibodies …
Beyond conventional immune-checkpoint inhibition—novel immunotherapies for renal cell carcinoma
The management of advanced-stage renal cell carcinoma (RCC) has been transformed by
the development of immune-checkpoint inhibitors (ICIs). Nonetheless, most patients do not …
the development of immune-checkpoint inhibitors (ICIs). Nonetheless, most patients do not …
Regulatory T cells in cancer immunosuppression—implications for anticancer therapy
Y Togashi, K Shitara, H Nishikawa - Nature reviews Clinical oncology, 2019 - nature.com
Regulatory T (Treg) cells, an immunosuppressive subset of CD4+ T cells characterized by
the expression of the master transcription factor forkhead box protein P3 (FOXP3), are a …
the expression of the master transcription factor forkhead box protein P3 (FOXP3), are a …
Actively personalized vaccination trial for newly diagnosed glioblastoma
N Hilf, S Kuttruff-Coqui, K Frenzel, V Bukur… - Nature, 2019 - nature.com
Patients with glioblastoma currently do not sufficiently benefit from recent breakthroughs in
cancer treatment that use checkpoint inhibitors,. For treatments using checkpoint inhibitors to …
cancer treatment that use checkpoint inhibitors,. For treatments using checkpoint inhibitors to …
Monocytes in the tumor microenvironment
S Ugel, S Canè, F De Sanctis… - Annual Review of …, 2021 - annualreviews.org
Immunotherapy has revolutionized cancer treatment over the past decade. Nonetheless,
prolonged survival is limited to relatively few patients. Cancers enforce a multifaceted …
prolonged survival is limited to relatively few patients. Cancers enforce a multifaceted …
CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors
H Wang, F Franco, YC Tsui, X Xie, MP Trefny… - Nature …, 2020 - nature.com
Depleting regulatory T cells (Treg cells) to counteract immunosuppressive features of the
tumor microenvironment (TME) is an attractive strategy for cancer treatment; however …
tumor microenvironment (TME) is an attractive strategy for cancer treatment; however …
Towards personalized, tumour-specific, therapeutic vaccines for cancer
Z Hu, PA Ott, CJ Wu - Nature Reviews Immunology, 2018 - nature.com
Cancer vaccines, which are designed to amplify tumour-specific T cell responses through
active immunization, have long been envisioned as a key tool of effective cancer …
active immunization, have long been envisioned as a key tool of effective cancer …
The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies
A Daei Sorkhabi, L Mohamed Khosroshahi… - Frontiers in …, 2023 - frontiersin.org
The successful outcomes of chimeric antigen receptor (CAR) T-cell therapy in treating
hematologic cancers have increased the previously unprecedented excitement to use this …
hematologic cancers have increased the previously unprecedented excitement to use this …
[PDF][PDF] Treatment of renal cell carcinoma: current status and future directions
Over the past 12 years, medical treatment for renal cell carcinoma (RCC) has transitioned
from a nonspecific immune approach (in the cytokine era), to targeted therapy against …
from a nonspecific immune approach (in the cytokine era), to targeted therapy against …
Teaching an old dog new tricks: next-generation CAR T cells
N Tokarew, J Ogonek, S Endres… - British journal of …, 2019 - nature.com
Adoptive T cell therapy (ACT) refers to the therapeutic use of T cells. T cells genetically
engineered to express chimeric antigen receptors (CAR) constitute the most clinically …
engineered to express chimeric antigen receptors (CAR) constitute the most clinically …